Inovio reports positive results from Zika vaccine clinical trial

Inovio Pharmaceuticals has reported positive safety and immune response results from a first-in-man, multi-centre Phase I trial (ZIKA-001) of its DNA-based vaccine (GLS-5700) for the treatment of Zika virus.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news